Pancreatic Enzyme Replacement and Glucose Regulation in Type 1 Diabetes

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

September 2, 2022

Primary Completion Date

March 22, 2024

Study Completion Date

March 22, 2024

Conditions
Type 1 Diabetes
Interventions
DRUG

CREON

The study will enroll 6-10 adult subjects with T1D who will receive both pancreatic enzyme replacement (CREON) or placebo each for 7 days in a random order. The effect of the intervention will be monitored by continuous glucose monitoring, diet recording, capsule counts, a mixed-meal tolerance test, and a survey to assess symptoms of PEI. This study design will allow for estimation of the effect of pancreatic enzyme replacement on the measured parameters.

DRUG

Placebo

Placebo

Trial Locations (1)

37232

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
lead

Vanderbilt University Medical Center

OTHER